On April 27-28, 2017 in Astana, the International Scientific and Practical Conference “Development of Health Technology Assessment in the Eurasian Economic Union” was organized by the Republican Center for Health Development of the Republic of Kazakhstan, the Kazakhstan Association for the Assessment of Health Technologies, Evidence Medicine and Pharmacoeconomic Research “KazSPOR”, Health Technology Assessment Association and the Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian Federation.
In order to discuss the main directions for the development of health technology assessment, as well as to consider possible obstacles at the stage of the formation of HTA in Russia, the sessions “Practical aspects of using health technology assessment” and “Implementation of HTA in the countries of the Eurasian Economic Union, prospects for integration” were organized, in which representatives of the Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian Federation, leading experts in the field of HTA and drug provision of the EU and EEU countries took part.
According to the acting Head of the Republican Center for Health Development of the Ministry of Health of the Republic of Kazakhstan Ainur Ayipkhanova, “the prerequisite for the ensuring of the proper level of quality of medical care for the population is the introduction of methods of HTA in day-to-day clinical practice”.
Vitaly Omelyanovskiy, the Head of the Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian Federation, noted that the first steps to introduce the HTA in Russia had been taken. He added that “Like the Republic of Kazakhstan, Russia could become the platform for specialists training in the area of HTA for the EEU countries”.
The conference discussed the issues of drug provision financing in the countries of the EEU and the prospects for the functioning of a united market of medical devices within the framework of the EEU, international experience of integration in the HTA and the world experience of pricing systems for original and reproduced medicines.